Sylvant

Product manufactured by Eusa Pharma (Uk) Ltd

Application Nr Approved Date Route Status External Links
BLA125496 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Sylvant Is Indicated For The Treatment Of Patients With Multicentric Castleman's Disease (Mcd) Who Are Human Immunodeficiency Virus (Hiv) Negative And Human Herpesvirus-8 (Hhv-8) Negative. Sylvant Is An Interleukin-6 (Il-6) Antagonist Indicated For The Treatment Of Patients With Multicentric Castleman's Disease (Mcd) Who Are Human Immunodeficiency Virus (Hiv) Negative And Human Herpesvirus-8 (Hhv-8) Negative. ( 1 ) Limitations Of Use Sylvant Was Not Studied In Patients With Mcd Who Are Hiv Positive Or Hhv-8 Positive Because Sylvant Did Not Bind To Virally Produced Il-6 In A Nonclinical Study. Limitations Of Use Sylvant Was Not Studied In Patients With Mcd Who Are Hiv Positive Or Hhv-8 Positive Because Sylvant Did Not Bind To Virally Produced Il-6 In A Nonclinical Study.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Siltuximab

Comments